Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GMP for Sport

This article was originally published in The Tan Sheet

Executive Summary

Manufacturer Century Foods International became the first firm to receive certification under NSF International's recently announced GMP for Sport program, according to NSF. The GMP program "supports" NSF's Athletic Banned Substances Certification Program but also is an independent registration, the firm states. Forsyth, Missouri-based National Enzyme also received GMP for Sport certification, according to the NSF website. Additionally, the addition of Infinty2's InfiAid to the Athletic Banned Substances Program Certification list also was finalized ("1The Tan Sheet" July 24, 2006, p.5)...

You may also be interested in...

NSF Banned Athletic Substances Program Gains International Momentum

The partnership between the Canadian Centre for Ethics in Sport (CCES) and third-party testing firm NSF International has drawn the attention of several European countries, according to NSF's Kathy Jordan

Sandoz Stands Alone As It Completes Novartis Spinoff

Sandoz has heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” after completing its long journey towards independence by separating from former parent company Novartis.

Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says

The former principal deputy commissioner outlined what she sees as the future data requirements for real world evidence and why cell and gene therapy will lead the way.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts